MyFinsight
Home
Blog
About
Contact
Proceeds from debt, net
$489M
Other
$3M
Net cash provided by
(used in) financing...
$7M
(141.18%↑ Y/Y)
Deferred income taxes
$27M
Depreciation and
amortization
$2M
Canceled cashflow
$485M
Loss on debt
extinguishment
-$18M
something is missing
$2M
Net (decrease)
increase in cash and cash...
-$20M
Canceled cashflow
$7M
Sales and maturities
of debt securities
$6M
Net income
$89M
Stock-based compensation
expense
$9M
something is missing
$9M
Impairment of tangible and
intangible assets
$6M
Amortization of right-of-use
assets
$2M
Canceled cashflow
$41M
Repayments of debt
$333M
(8225.00%↑ Y/Y)
Cash paid for
repurchases of common stock
$126M
(1045.45%↑ Y/Y)
Settlement of equity awards
$21M
(600.00%↑ Y/Y)
Transaction costs related to
debt refinancing
$5M
Net cash used in
investing activities
-$19M
(-280.00%↓ Y/Y)
Net cash (used in)
provided by operating...
-$9M
(-112.00%↓ Y/Y)
Canceled cashflow
$6M
Canceled cashflow
$115M
Accounts receivable
$20M
Other current and
noncurrent assets
$18M
Other adjustments,
net
$2M
Current inventories
$1M
Purchases of property and
equipment
$20M
(300.00%↑ Y/Y)
Other current and
noncurrent liabilities
-$86M
Purchases of investments
in debt securities
$5M
(0.00%↑ Y/Y)
Accrued legal and
settlement expenses
-$38M
Back
Back
Cash Flow
indivior-logo-svg
Indivior Pharmaceuticals, Inc. (INDV)
indivior-logo-svg
source: myfinsight.com
Indivior Pharmaceuticals, Inc. (INDV)